By Chris Wack
MeiraGTx Holdings PLC said it received a $30 million payment from Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Cos. of Johnson & Johnson, for a clinical milestone in a Phase 3 trial of botaretigene sparoparvovec.
Botaretigene sparoparvovec is an investigational gene therapy for the treatment of X-linked retinitis pigmentosa. The Phase 3 Lumeos trial is a global study of botaretigene sparoparvovec which is now dosing participants.
MeiraGTx and Janssen are jointly developing botaretigene sparoparvovec as part of a broader collaboration to develop and commercialize gene therapies for the treatment of inherited retinal diseases.
MeiraGTx remains eligible to receive additional development and commercial milestones for botaretigene sparoparvovec as well as for other programs as part of the collaboration agreement.
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires